文献速递哮喘

Tezepelumab在重度未控制哮喘中的长期安全性与疗效:DESTINATION随机安慰剂对照扩展研究

Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
PubMed 文献 · Lancet Respir Med · 2023-01-23

DESTINATION为3期随机双盲安慰剂对照长期扩展研究,纳入NAVIGATOR和SOURCE研究的重度未控制哮喘患者,总治疗104周。Tezepelumab组不良事件和严重不良事件暴露调整发生率低于安慰剂组,且104周内哮喘年化急性发作率显著降低,安全性良好且疗效持续。

要点

  • Tezepelumab 210 mg每4周皮下注射治疗104周,安全性与安慰剂相比无新增风险。

核心结论

  • Tezepelumab治疗最长2年耐受性良好,在重度未控制哮喘患者中持续、具有临床意义地减少哮喘急性发作。

研究设计与样本

  • DESTINATION为3期、多中心、随机、双盲、安慰剂对照长期扩展研究,覆盖18个国家182个中心。
  • 纳入年龄12-80岁、在母研究NAVIGATOR或SOURCE中治疗依从性良好的重度未控制哮喘患者,所有参与者重新随机分组。
  • 既往接受tezepelumab者继续皮下注射tezepelumab 210 mg每4周;既往接受安慰剂者按1:1重新随机接受tezepelumab 210 mg每4周或安慰剂每4周。
  • 包括母研究在内的总治疗时长为104周,主要终点为不良事件和严重不良事件的暴露调整发生率,次要终点为年化哮喘急性发作率。

临床怎么用

  • 对重度未控制哮喘且既往未使用生物制剂者,可考虑tezepelumab 210 mg每4周皮下注射,长期治疗至104周安全且持续减少急性发作。

局限性

  • 本研究为扩展研究,仅纳入母研究中治疗依从性良好的参与者,可能限制外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin. The drug has been tested previously in the phase 3 NAVIGATOR (NCT03347279) and SOURCE (NCT03406078) studies, and was subsequently approved as a treatment for severe asthma. This extension study recruited from NAVIGATOR and SOURCE and aimed to evaluate the long-term safety and efficacy of tezepelumab in individuals with severe, uncontrolled asthma. METHODS: DESTINATION was a phase 3, multicentre, randomised, double-blind, placebo-controlled, long-term extension study. The study was done across 182 sites (including hospitals, clinics, medical centres, clinical trial centres, and private practices) in 18 countries. Participants (aged 12-80 years) were required to have good treatment compliance in the parent study. Randomisation was stratified by the parent study and all participants were re-randomised. Those who were previously randomised to receive tezepelumab in either parent study continued treatment of subcutaneous tezepelumab (210 mg every 4 weeks); those who were previously randomised to receive placebo in either parent study were re-randomised 1:1 to receive either subcutaneous tezepelumab (210 mg every 4 weeks) or placebo (every 4 weeks) using a randomisation list prepared by a computerised system. Total treatment duration (including the parent studies) was 104 weeks for all groups. Participants, investigators, and site staff were masked to treatment assignment. The primary endpoints were exposure-adjusted incidence of adverse events and serious adverse events and the secondary endpoint was the annualised asthma exacerbation rate; these were assessed from week 0 of the parent studies to week 104 of DESTINATION in all participants who were randomised and who received at least one dose of tezepelumab or placebo in either of the parent studies. The trial is registered with ClinicalTrials.gov, NCT03706079, and is closed to new participants. FINDINGS: Participants were recruited between Jan 7, 2019, and Oct 15, 2020. For individuals who initially received tezepelumab (n=528) in NAVIGATOR, incidence of adverse events over 104 weeks was 49·62 (95% CI 45·16 to 54·39) per 100 patient-years, compared with 62·66 (56·93 to 68·81) for those receiving placebo (n=531; difference -13·04, 95% CI -17·83 to -8·18). For serious adverse events, incidence was 7·85 (6·14 to 9·89) per 100 patient-years for individuals who initially received tezepelumab and 12·45 (9·97 to 15·35) for those who received placebo (difference -4·59, -7·69 to -1·65). In SOURCE, incidence of adverse events was 47·15 (36·06 to 60·56) per 100 patient-years for those who initially received tezepelumab (n=74) and 69·97 (54·54 to 88·40) for those who received placebo (n=76; difference -22·82, -34·77 to -10·01). For serious adverse events, incidence was 13·14 (7·65 to 21·04) per 100 patient-years for those who initially received tezepelumab and 17·99 (10·66 to 28·44) for those who received placebo (difference -4·85, -14·88 to 4·53). Tezepelumab reduced the annualised asthma exacerbation rate over 104 weeks compared with placebo. In participants initially from NAVIGATOR, the annualised asthma exacerbation rate ratio over 104 weeks was 0·42 (95% CI 0·35 to 0·51); in those initially from SOURCE, the ratio over 104 weeks was 0·61 (0·38 to 0·96). INTERPRETATION: Tezepelumab treatment was well tolerated for up to 2 years and resulted in sustained, clinically meaningful reductions in asthma exacerbations in individuals with severe, uncontrolled asthma. These findings are consistent with previous randomised, placebo-controlled studies and show the long-term safety and sustained efficacy of tezepelumab in individuals with severe, uncontrolled asthma. FUNDING: AstraZeneca and Amgen.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Menzies-Gow, Wechsler, Brightling, et al. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Lancet Respir Med. 2023. PMID: 36702146. doi:10.1016/S2213-2600(22)00492-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。